In a nationwide study in Germany, a total of 381 Streptococcus pyogenes were collected. Erythromycin A-resistant strains were characterized for the underlying resistance genotype, showing 55.6% had the efflux type mef(A), 31.5% had erm(A), and 13.0% had erm(B). A total of 23 different multilocus sequence types were observed.
In a nationwide study in Germany, a total of 381 Streptococcus pyogenes were collected. Erythromycin A-resistant strains were characterized for the underlying resistance genotype, showing 55.6% had the efflux type mef(A), 31.5% had erm(A), and 13.0% had erm(B). A total of 23 different multilocus sequence types were observed.
Streptococcus pyogenes is a major cause of human disease, producing both mild (e.g., pharyngitis) and severe (e.g., toxic shock-like syndrome, necrotizing fasciitis) infections (6) . Macrolides are treatment alternatives to penicillin, valuable especially in patients allergic to ␤-lactams. Different phenotypes of macrolide resistance have been recognized. Strains of the M phenotype are resistant to 14-and 15-member macrolides, due to the presence of mef(A) genes, conferring efflux of the antibiotic out of the bacterial cell. These strains remain susceptible to 16-member ring macrolides and clindamycin (16) .
Target site modification is mostly based on dimethylation of an adenine residue (A2058) of the 23S rRNA domain V through the action of a family of enzymes encoded by erm class genes. Two classes of methylase genes, erm(B) and erm(A), subclass erm(TR), have been described (15) . Some of the constitutively resistant erm(B)-positive S. pyogenes strains were found to be telithromycin resistant (13) , but telithromycin retains activity against strains possessing the other macrolide resistance genotypes, such as erm(A) and mef(A).
In the present study, consecutive clinical isolates (n ϭ 381) were collected between November 1999 and March 2000 from outpatients with S. pyogenes infections. S. pyogenes isolates were identified by hemolysis on sheep blood agar; Lancefield grouping, using a commercially available agglutination technique (Slidex, Streptokit; BioMérieux, Marcy-L'Etoile, France); and a positive pyrrolidonyl-arylamidase test. MIC testing was performed by the broth microdilution method as recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (10) . Streptococcus pneumoniae ATCC 49619 was used as a control strain. Current NCCLS interpretive criteria were used to define antimicrobial resistance (11) . In the case of telithromycin, breakpoints proposed by Fuchs et al. (8) of Յ1 and Ն4 mg/ml were used for susceptible and resistant category, respectively. NCCLS breakpoints for roxithromycin were not available. The macrolide resistance phenotype was determined on the basis of the pattern of susceptibility to macrolide-lincosamide-streptogramin B (MLS) antibiotics and confirmed on the basis of the double-disk (erythromycin A plus clindamycin) agar diffusion test (9) .
Macrolide-resistant S. pyogenes strains were tested by PCR for the presence of erm(A), erm(B), or mef(A) (13, 14) .
The two telithromycin-resistant strains were screened for further resistance determinants, including ere(A), ere(B), msr(A), mph(A), mph(B), and mph(C), as described previously (16, 17) . The primers and PCR conditions used to amplify 23S rRNA were identical to those used to amplify the S. pneumoniae gene (17) . emm typing was performed as described by Podbielski et al. (12) . Multilocus sequence typing was performed as described by Enright et al. for all macrolide-resistant strains (7) .
S. pyogenes isolates (n ϭ 381) were predominantly isolated from the throat (n ϭ 256 [67.2%]) and skin (n ϭ 83 [21.8%]). Thirteen strains were isolated from the ear, and 29 were isolated from other sources. Data on antibiotic resistance of all strains and macrolide-resistant strains are presented in Table  1 . Resistance to erythromycin A was detected in 54 strains (14.2%). One strain (MSR 141) was levofloxacin-resistant (MIC, Ն32 g/ml), and two strains were resistant to telithromycin. Additional data on macrolide-resistant strains are presented in Table 2 . S. pyogenes strains belonged to the following resistance genotypes: mef(A) (n ϭ 30, 55.6%), erm(A) (n ϭ 17, 31.5%), and erm(B) (n ϭ 7, 13.0%). All mef(A)-positive strains showed the M phenotype as well as a slightly elevated telithromycin MIC at which 90% of the isolates tested are inhibited (MIC 90 ). All erm(A)-positive strains showed inducible resistance to clindamycin. erm(B)-positive strains were inducibly clindamycin resistant or showed the cMLS B phenotype. Two of the erm(B)-positive strains were telithromycin resistant. The two telithromycin-resistant strains (MSR 63, telithromycin MIC, 32 g/ml; MSR 610, telithromycin MIC, 4 g/ml; both cMLS B phenotypes) did not contain additional macrolide resistance mechanisms, and no mutations were present in L4 or L22 ribosomal proteins or in the 23S rRNA sequences. In addition, both strains were found to harbor an erm(B) determinant that differed in several ways from the erm(B) determinant described in either the canonical Tn1545 or Tn917 element (15) . Strains MSR 63 and MSR610 had a Tn917-like promoter but a 27-amino-acid leader peptide like that found in Tn1545 (Table 3 ). The two resistant strains also showed a change near the ribosome-binding site (RBS) upstream of the coding sequence. This change may impart better binding of the ribosome and more efficient translation. In addition, these strains had three amino acid differences (I75T, S100N, and H118R) compared to the erm(B) coding sequence in Tn1545; however, S100N is found in the erm(B) sequence in Tn917 without conferring ketolide resistance. I75T was also present in the erm(BC) gene found in the Escherichia coli plasmid pIP1527 (3). Only H118R is unique to these ketolide-resistant strains.
emm typing of erythromycin A-resistant (n ϭ 54) and randomly selected macrolide-susceptible (n ϭ 60) S. pyogenes isolates showed that strains of emm types 77 (n ϭ 19, 45.2%) and 4 (n ϭ 13, 26.2%) were found significantly more often among resistant isolates (Table 4) .
Antibiotic resistance is of growing concern with regard to S. pyogenes isolates from Germany. Previous investigators have reported on macrolide resistance rates among S. pyogenes of a 50% and 90%, MIC 50 and MIC 90 , respectively. b Breakpoints: penicillin G, intermediate, 0.1 to 1 g/ml, resistant, Ն2 g/ml; erythromycin A, intermediate, 0.5 g/ml, resistant, Ն1 g/ml; clarithromycin, intermediate, 0.5 g/ml, resistant, Ն1 g/ml; azithromycin, intermediate, 1 g/ml, resistant, Ն2 g/ml; clindamycin, intermediate, 0.5 g/ml, resistant, Ն1 g/ml; and levofloxacin, intermediate, 4 g/ml, resistant, Ն8 g/ml (11) .
c Roxithromycin breakpoints are not NCCLS approved. For telithromycin breakpoints of Յ1 g/ml, Ն4 g/ml was used (8) . d ND, no data. e All strains were inducibly clindamycin resistant (Table 2) .
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4% in 1992 to 1993 (5), 1.6% in 1997 (18), 12.7% in 1996 to 1998 (1), 7.9% in 1997 (2), and 13.7% in 2000 (13) . In an international study including 1,485 isolates of S. pyogenes, almost 10% of S. pyogenes isolates were erythromycin A resistant. There was a wide heterogeneity of resistance, with high levels of macrolide resistance in Poland (42%), Hong Kong (28%), Italy (25%), Portugal (24%), and Spain (21%) and no macrolide resistance in Indonesia, Austria, Belgium, The Netherlands, or the United Kingdom (4).
In the present study, stable associations between emm type and MLST were observed. Twelve new STs were described. Of note, three strains (MSR 144, MSR 206, and MSR 333) showed an MLST emm type combination that had not been described to date. A total of 27 different STs were observed in the present investigation, but three clones were identified to account for more than 50% of macrolide resistance of S. pyogenes in Germany: mef(A)-positive emm type 4 isolates (ST 39, n ϭ 10 plus 3 single-locus variants), an erm(A)-positive clone (B) in Streptococcus sanguis (pAM77), S. pneumoniae (Tn1545), and the two ketolide-resistant S. pyogenes strains are compared (15) . Boldface residues delineate the promoter region, lowercase letters represent the RBS before a leader peptide (underlined) of 36 amino acids (pAM77) or 27 amino acids (Tn1545, MSR 63, MSR610). (TAA is a stop codon.) Only residues that differ from pAM77 erm(B) are shown. 
